Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling

[1]  P. Erben,et al.  MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure , 2014, Leukemia.

[2]  S. Brandner,et al.  A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling , 2014, Journal of Cell Science.

[3]  W. Slayton,et al.  Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , 2014, Front. Oncol..

[4]  Y. Doki,et al.  New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis , 2013, International journal of cancer.

[5]  M. Caligiuri,et al.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.

[6]  Tao Jiang,et al.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. , 2013, Cancer letters.

[7]  P. Frankel,et al.  p130Cas: a key signalling node in health and disease. , 2013, Cellular signalling.

[8]  R. Scharfmann,et al.  Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl , 2013, Diabetologia.

[9]  D. Marin,et al.  The next questions in chronic myeloid leukaemia and their answers. , 2013, Current opinion in hematology.

[10]  G. Basso,et al.  Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. , 2013, Biochemical pharmacology.

[11]  I. Ben-Sahra,et al.  Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. , 2012, Journal of Molecular Cell Biology.

[12]  S. Heidorn,et al.  Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. , 2011, Cancer cell.

[13]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[14]  Jiankai Xu,et al.  Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. , 2011, International journal of oncology.

[15]  P. Frankel,et al.  Neuropilin-1 Signaling through p130Cas Tyrosine Phosphorylation Is Essential for Growth Factor-Dependent Migration of Glioma and Endothelial Cells , 2011, Molecular and Cellular Biology.

[16]  G. Robert,et al.  Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. , 2010, Cancer research.

[17]  P. Ding,et al.  BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.

[18]  C. Antonescu,et al.  Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib , 2010, Molecular Cancer Research.

[19]  H. Kantarjian,et al.  Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase , 2010, Cancer.

[20]  P. C. de Witt Hamer.  Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. , 2010, Neuro-oncology.

[21]  M. Weller,et al.  Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide , 2010, Journal of Neuro-Oncology.

[22]  M. Litzow.  Imatinib resistance: obstacles and opportunities. , 2009, Archives of pathology & laboratory medicine.

[23]  P. Frankel,et al.  Chondroitin sulphate‐modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas‐mediated pathway , 2008, EMBO reports.

[24]  C. Turner,et al.  Paxillin comes of age , 2008, Journal of Cell Science.

[25]  James D. Griffin,et al.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia , 2007, Nature Reviews Cancer.

[26]  M. Dragunow,et al.  The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells , 2006, Neuroscience.

[27]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[28]  H. Augustin.  Methods in Endothelial Cell Biology , 2004, Springer Lab Manuals.

[29]  M. Paul,et al.  Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.

[30]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[31]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[32]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[33]  J. Parsons,et al.  Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells , 2001, Oncogene.

[34]  J. Guan,et al.  Focal adhesion kinase in integrin-mediated signaling. , 1999, Frontiers in bioscience : a journal and virtual library.

[35]  Thomas Mattair,et al.  Obstacles and Opportunities , 1993 .

[36]  H. Woodrow,et al.  : A Review of the , 2018 .

[37]  V.M. Zohrabian,et al.  Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. , 2009, Anticancer research.

[38]  Michael Berens,et al.  A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. , 2007, Biophysical journal.

[39]  F P Retief,et al.  [The first ten years]. , 1979, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.